Highest-materiality recent filing
Spectral AI appoints Darcy Bajko as Chief Commercial Officer effective July 31, 2026
Darcy Bajko appointed CCO, start date July 31, 2026; reports to CEO Vince Capone.
FDA De Novo clearance for DeepView System for Burn Indication; commercial distribution authorized in US.
Spectral AI receives FDA De Novo clearance for DeepView System for burn indication
FDA granted De Novo Classification for DeepView System, authorizing commercial distribution in the US.
Spectral AI formalizes CEO Vincent Capone’s employment with $500k base, bonus, and RSU grant
Annual base salary of $500,000; eligible for annual target bonus up to 100% of base, minimum $250,000.
Spectral AI appoints David McGuire as CFO, effective May 4, 2026
David McGuire named CFO effective May 4, 2026; reports to CEO Vincent Capone.
Spectral AI Q4 net income $0.6M; FY 2025 revenue $19.7M; guides 2026 revenue ~$18.5M
Q4 2025 net income $0.6M ($0.02 diluted EPS) vs net loss ($7.7M) in Q4 2024.
Spectral AI awarded $31.7M additional BARDA funding for DeepView System
BARDA awards $31.7 million in non-dilutive funding to accelerate DeepView System development.
Spectral AI appoints Vincent S. Capone as CEO effective Feb 9, 2026
Board dissolved Office of the Chairman; Capone previously served as CFO and General Counsel.
Spectral AI's Chief Commercial Officer Jeremiah Sparks steps down; 90-day consulting agreement
Jeremiah Sparks resigned as CCO effective Feb 1, 2026 to pursue other opportunities, no disagreement with company.
Director Colin Bristow resigns from Spectral AI board effective Jan. 5, 2026
Colin Bristow resigned as director effective January 5, 2026.
Spectral AI raises $7.6M in offering of common stock, warrants, pre-funded warrants
Sold 3,065,000 shares at $1.90, plus 4,000,000 warrants ($2.51 exercise) and 935,000 pre-funded warrants ($0.0001).
Spectral AI Q2 2025 revenue down 32% to $5.1M; net loss widens to $7.9M
R&D revenue $5.1M in Q2 2025 vs. $7.5M in Q2 2024 (down 32.0%), reflecting completion of BARDA clinical trials.
Spectral AI submits De Novo request to FDA for DeepView burn assessment system
Spectral AI submitted a De Novo request to the FDA for its DeepView System on June 30, 2025.
Spectral AI dismisses KPMG as auditor, engages Forvis Mazars for fiscal 2025
Audit Committee unanimously voted to dismiss KPMG effective May 29, 2025.
Spectral AI names Stanley Micek as permanent Chief Operating Officer
Stanley Micek, previously interim COO since May 2024, appointed permanent COO effective May 30, 2025.
Annual meeting held May 28, 2025; 15.55M shares (60.8% of outstanding) represented.
Spectral AI Q1 net income $2.9M; cash $14.1M; FDA De Novo submission planned H1 2025
Q1 2025 R&D revenue $6.7M (+6% YoY); net income $2.9M vs net loss $(3.2)M in Q1 2024.
Spectral AI reports FY2024 R&D revenue $29.6M; net loss $(15.3)M; plans FDA submission by Q2 2025
FY2024 R&D revenue $29.6M (+63.5% YoY); net loss $(15.3)M ($(0.85)/share) vs $(20.9)M in FY2023.
Spectral AI closes $15M debt facility with $2.7M equity raise; $14M cash for DeepView launch
Debt financing of up to $15M from Avenue Capital Group; initial draw $8.5M, maturity March 2028, interest-only for 15 months.
DeepView sensitivity 86.6% vs burn physicians 40.8% at image-wise level; pixel-wise 81.9% vs 38.8%.
Spectral AI enters $5M equity purchase deal with Liqueous LP; initial draw of 500k shares at $1.80
Securities purchase agreement allows up to $5M in common stock sales to Liqueous LP over six-month commitment period.
Spectral AI enters $5M registered direct offering with Liqueous LP at $1.38/share
Sold 920,000 common shares and pre-funded warrants for 725,000 shares at $1.38 per unit.
Spectral AI raises $449,694 in registered direct offering of 270,900 shares at $1.66/share
Sold 270,900 shares of common stock at $1.66 per share, gross proceeds $449,694.
Spectral AI regains Nasdaq listing compliance; moot letter received Dec 20
Received Nasdaq 'moot' letter on Dec 20, 2024 confirming compliance with all listing standards.
Spectral AI faces Nasdaq delisting for failing $35M market value rule; hearing requested
Nasdaq notified Spectral AI on Dec. 5, 2024 that common stock (MDAI) will be delisted for failing to maintain minimum $35M market value of listed securities by Dec. 2, 2024.
Spectral AI CEO Peter Carlson resigns; founder Dr. DiMaio returns as Chairman; Office created
Peter M. Carlson resigned as CEO and director effective Oct 14, 2024; will serve as consultant for 15 months at $27,500/month.
Spectral AI posts investor deck showing 2024E rev ~$28M (+56% YoY) and 85% burn trial enrollment
H1 2024 revenue $13.8M; FY 2023 revenue $18M, FY 2024 expected ~$28M.
Board member and largest shareholder Erich Spangenberg leads the inquiry, sending a follow-up letter to Nasdaq on July 15, 2024.
Spectral AI alleges naked short selling inflated float >40%; requests Nasdaq, state probes
Claims NOBO and OBO lists exceed total public float by over 40%, indicating naked short selling.
Spectral AI receives Nasdaq delisting notice for failing $35M market value requirement
Nasdaq notified Spectral AI on June 3, 2024, of non-compliance with minimum market value of listed securities ($35M).
Board expanded to seven; Erich Spangenberg appointed as director, returning after declining reelection.
Spectral AI COO Dr. Niko Pagoulatos resigns; Stan Micek named interim COO
Dr. Niko Pagoulatos resigned as COO on March 29, 2024; resignation not due to any disagreement with the Company.
Spectral AI names Jeremiah Sparks CCO; base salary $295K plus options
Jeremiah Sparks appointed Chief Commercialization Officer effective April 1, 2024.
Spectral AI reports FY2023 net loss of $20.9M ($1.48/sh); guides FY2024 revenue $28M
Q4 2023 R&D revenue $5.3M; FY2023 R&D revenue $18.1M (down from $25.4M YoY).
Spectral AI enters $30M standby equity purchase agreement with Yorkville, gets $5M note
Company may sell up to $30M of common stock to Yorkville at 97% of lowest 3-day VWAP.
Spectral AI appoints Peter Carlson as CEO; Fan steps down; reaffirms FY2024 revenue guidance ~$28M
Wensheng Fan resigned as CEO and director effective Feb 29, 2024; becomes Chief Innovation Strategist.
Spectral AI receives UKCA authorization for burn wound diagnosis; expects H2 2024 revenue
DeepView AI®-Burn obtained UKCA authorization for aiding burn wound diagnosis in the United Kingdom.
Spectral AI projects $28M 2024 revenue; $149M BARDA contract advances burn product
2023E revenue $17.4M; 2024E revenue guidance $28M, up 61% YoY.
Dr. J. Michael DiMaio appointed to board effective Feb 7, 2024, filling vacancy left by Michael Murphy.
Spectral AI updates on regulatory progress; expects UK DeepView revenue in H2 2024
Submitted DeepView AI-Burn for UKCA marking; response expected 1H 2024; first UK revenue in H2 2024.
Director Michael Murphy resigns from Spectral AI board effective immediately
Michael Murphy resigned as director on January 30, 2024.
Spectral AI enters $10M equity purchase agreement with B. Riley
Company can sell up to $10M of common stock to B. Riley at its discretion over 24 months.
Spectral AI names Peter M. Carlson as CFO effective Jan 3, 2024; base $475K, bonus $475K, 150K RSUs
Peter M. Carlson appointed CFO effective January 3, 2024; previously CFO at MiMedx Group (advanced wound care).
Spectral AI appoints largest shareholder Erich Spangenberg to Board and Executive Committee Chair
Erich Spangenberg appointed to Board and as Chairman of Executive Committee and Nominating & Corporate Governance Committee, effective immediately.
Spectral AI Q3 revenue $3.4M, net loss $10.6M; affirms FY2023 guidance $17.4M
Q3 revenue $3.4M (down 51% YoY); net loss $10.6M ($0.77/share) vs loss $0.4M in Q3 2022.
Spectral AI subsidiary awarded up to $149M BARDA contract for DeepView burn imaging device
Total BARDA contract value up to $149M; initial award of $55M for DeepView clinical validation and FDA clearance.
Spectral AI completes business combination with Spectral MD; begins trading on Nasdaq Sept 12
Business Combination closed Sept 11; RCLF renamed Spectral AI, Inc.; common stock and warrants trade on Nasdaq as MDAI and MDAIW.
Rosecliff shareholders approve Spectral MD combination; 46% of public shares redeemed
Stockholders approved business combination: 6,341,342 for, 15,120 against, 6,000 abstain.
Nasdaq notified Rosecliff on July 24, 2023 that its securities will be delisted for non-compliance with minimum 500,000 publicly held shares requirement.
DeepView System received FDA Breakthrough Device Designation for burn indication in 2018.
On May 30, 2025, the Company announced that Stanley Micek has been named the Company’s Chief Operating Officer (“COO”).
Peter M. Carlson resigned as the Chief Executive Officer of Spectral AI, Inc. (the “Company”) and as a director of the Company on October 14, 2024.
Following the Annual Meeting (as defined below), the board of directors (the “ Board ”) of Spectral AI, Inc., a Delaware corporation (the “ Company ”) unanimously approved the expansion of the Board from six to seven members and appointed Erich Spangenberg to serve as a director on the Company’s Board.
Dr. Niko Pagoulatos resigned as the Chief Operating Officer of Spectral AI, Inc. (the “Company”) on March 29, 2024.
The Company has appointed Stan Micek to the position of interim Chief Operating Officer, effective April 8, 2024.
Wensheng Fan resigned as the Chief Executive Officer of Spectral AI, Inc. (the “Company”) and as a director of the Company on February 29, 2024. Mr. Fan has agreed to serve the Company as Chief Innovation Strategist to continue to provide support for its current technology and to assist in the transition of the Chief Executive Officer.
the Board of Directors of the Company (the “Board”) have appointed Peter M. Carlson to the position of Chief Executive Officer and Vincent S. Capone to the position of Chief Financial Officer and General Counsel effective February 29, 2024.
The board of directors (the “ Board ”) of Spectral AI, Inc., a Delaware corporation (the “ Company ”) appointed Dr. J. Michael DiMaio to serve as director on the Company’s Board, effective immediately.
On January 30, 2024, Michael Murphy tendered his resignation as a director on the Board of Directors of the Company, with such resignation becoming effective immediately.
the Board of Directors of the Company (the “Board”) has appointed Peter M. Carlson to the position of Chief Financial Officer, effective January 3, 2024.
Upon commencement of Mr. Carlson’s employment with the Company, Nils Windler, who has been serving as Chief Financial Officer of the Company since 2021, will remain with the Company to work closely with Mr. Carlson, support an orderly transition of responsibility and provide financial accounting support to the Company.
The board of directors (the “ Board ”) of Spectral AI, Inc., a Delaware corporation (the “ Company ”) appointed Mr. Erich Spangenberg to serve as director on the Company’s Board, effective immediately.
Max materiality 0.85 · Median 0.65 · Most common event other_material